MA37700B1 - N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments - Google Patents
N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicamentsInfo
- Publication number
- MA37700B1 MA37700B1 MA37700A MA37700A MA37700B1 MA 37700 B1 MA37700 B1 MA 37700B1 MA 37700 A MA37700 A MA 37700A MA 37700 A MA37700 A MA 37700A MA 37700 B1 MA37700 B1 MA 37700B1
- Authority
- MA
- Morocco
- Prior art keywords
- arylcarboxamides
- quinolin
- yloxy
- hetero
- cyclohexyl
- Prior art date
Links
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 125000005842 heteroatom Chemical group 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title abstract 2
- -1 quinolin-4-yloxy Chemical group 0.000 title abstract 2
- 229940123407 Androgen receptor antagonist Drugs 0.000 title 1
- 239000003936 androgen receptor antagonist Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
La présente invention concerne les n-[4-(quinolin-4-yloxy)cyclohexyl (méthyl)](hétéro)arylcarboxamides, leurs intermédiaires et leurs procédés de production, leur utilisation pour traiter et/ou prévenir des maladies et leur utilisation en vue de la production de médicaments, ainsi que l'utilisation de ces derniers en vue du traitement et/ou de la prévention de maladies, dont, plus particulièrement, les maladies hyperprolifératives.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12004764 | 2012-06-26 | ||
| PCT/EP2013/063118 WO2014001247A1 (fr) | 2012-06-26 | 2013-06-24 | N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA20150269A1 MA20150269A1 (fr) | 2015-08-31 |
| MA37700B1 true MA37700B1 (fr) | 2018-03-30 |
Family
ID=48699019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37700A MA37700B1 (fr) | 2012-06-26 | 2013-06-24 | N-[4-(quinolin-4-yloxy)cyclohexyl(méthyl)](hétéro)arylcarboxamides utilisables en tant qu'antagonistes des récepteurs aux androgènes, leur production et leur utilisation en tant que médicaments |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9428460B2 (fr) |
| EP (1) | EP2864291B1 (fr) |
| JP (1) | JP6181172B2 (fr) |
| KR (1) | KR20150023880A (fr) |
| AP (1) | AP3919A (fr) |
| AR (1) | AR091565A1 (fr) |
| AU (1) | AU2013283543B2 (fr) |
| BR (1) | BR112014032538A2 (fr) |
| CA (1) | CA2877786C (fr) |
| CL (1) | CL2014003443A1 (fr) |
| CO (1) | CO7170167A2 (fr) |
| CR (1) | CR20140593A (fr) |
| CU (1) | CU20140144A7 (fr) |
| CY (1) | CY1118412T1 (fr) |
| DK (1) | DK2864291T3 (fr) |
| DO (1) | DOP2014000295A (fr) |
| EA (1) | EA028063B1 (fr) |
| EC (1) | ECSP14032516A (fr) |
| ES (1) | ES2609455T3 (fr) |
| HR (1) | HRP20161745T1 (fr) |
| HU (1) | HUE032306T2 (fr) |
| IL (1) | IL236146B (fr) |
| JO (1) | JO3342B1 (fr) |
| LT (1) | LT2864291T (fr) |
| MA (1) | MA37700B1 (fr) |
| ME (1) | ME02590B (fr) |
| MX (1) | MX2014016054A (fr) |
| NZ (1) | NZ703100A (fr) |
| PE (1) | PE20150154A1 (fr) |
| PH (1) | PH12014502869A1 (fr) |
| PL (1) | PL2864291T3 (fr) |
| PT (1) | PT2864291T (fr) |
| RS (1) | RS55500B1 (fr) |
| SG (1) | SG11201408254UA (fr) |
| SI (1) | SI2864291T1 (fr) |
| TN (1) | TN2014000532A1 (fr) |
| TW (1) | TWI600646B (fr) |
| UA (1) | UA115447C2 (fr) |
| UY (1) | UY34881A (fr) |
| WO (1) | WO2014001247A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017513954A (ja) * | 2014-04-22 | 2017-06-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| AR102537A1 (es) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| EP3452451A4 (fr) * | 2016-05-04 | 2019-11-13 | Bristol-Myers Squibb Company | Inhibiteurs d'indoleamine 2,3-dioxygénase et leurs méthodes d'utilisation |
| US10544099B2 (en) | 2016-05-04 | 2020-01-28 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328821A (en) | 1991-12-12 | 1994-07-12 | Robyn Fisher | Cold and cryo-preservation methods for human tissue slices |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| WO2002000624A2 (fr) | 2000-06-23 | 2002-01-03 | Eli Lilly And Company | Procedes et composes d'inhibition du mrp1 |
| CA2454538A1 (fr) | 2001-06-22 | 2003-01-03 | Kirin Beer Kabushiki Kaisha | Derives de la quinoleine et de la quinozoline pouvant inhiber l'auto- phosphorylation des recepteurs du facteur de croissance des hepatocytes, et composition pharmaceutique ainsi constituee |
| KR100863667B1 (ko) | 2002-09-11 | 2008-10-15 | 가부시끼가이샤 구레하 | 아민 화합물 및 그 용도 |
| US20050227932A1 (en) | 2002-11-13 | 2005-10-13 | Tianbao Lu | Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction |
| EP1590334B1 (fr) | 2003-01-30 | 2009-08-19 | Boehringer Ingelheim Pharmaceuticals Inc. | Derives de 2,4-diaminopyrimidine utiles en tant qu'inhibiteurs de l'enzyme pkc-theta |
| SE0302573D0 (sv) | 2003-09-26 | 2003-09-26 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| WO2005094251A2 (fr) | 2004-03-17 | 2005-10-13 | Glaxo Group Limited | Antagonistes du recepteur muscarinique a l'acetylcholine m3 |
| SE0401342D0 (sv) | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| WO2005117570A1 (fr) | 2004-05-27 | 2005-12-15 | Jack Saffron | Coupelle pour aliments empechant l'infestation par des parasites |
| WO2006052722A1 (fr) | 2004-11-09 | 2006-05-18 | Smithkline Beecham Corporation | Composes inhibiteurs de la phosphorylase du glycogene et compositions pharmaceutiques les comprenant |
| JO2787B1 (en) * | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| GB0509227D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
| GB0509224D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
| US20060293341A1 (en) | 2005-06-23 | 2006-12-28 | Vrej Jubian | Alkyl sulfonamide derivatives |
| CN101378747A (zh) | 2006-02-06 | 2009-03-04 | 昭和电工株式会社 | 增白皮肤病制剂 |
| US20110053931A1 (en) | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
| GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| WO2008064432A1 (fr) | 2006-12-01 | 2008-06-05 | The University Of Sydney | Composés moléculaires polycycliques |
| US8377949B2 (en) | 2007-08-16 | 2013-02-19 | Boehringer Ingelheim International Gmbh | Quinazolinedione chymase inhibitors |
| TWI469971B (zh) * | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| WO2009140549A1 (fr) | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinaisons d'inhibiteurs de vegf(r) et d'inhibiteurs du facteur de croissance d'hépatocyte (c-met) pour le traitement du cancer |
| AU2009300328A1 (en) | 2008-10-01 | 2010-04-08 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
| KR20120051022A (ko) | 2009-07-21 | 2012-05-21 | 길리애드 사이언시즈, 인코포레이티드 | 플라비비리데 바이러스의억제제 |
| WO2011029782A1 (fr) | 2009-09-11 | 2011-03-17 | Bayer Schering Pharma Aktiengesellschaft | Thiohydantoïnes à substitution hétéroarylméthyle, en tant que médicaments anticancer |
| WO2012009649A1 (fr) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Inhibiteurs mif et leurs utilisations |
-
2013
- 2013-06-24 EP EP13731325.0A patent/EP2864291B1/fr active Active
- 2013-06-24 AP AP2014008141A patent/AP3919A/en active
- 2013-06-24 SG SG11201408254UA patent/SG11201408254UA/en unknown
- 2013-06-24 EA EA201500039A patent/EA028063B1/ru not_active IP Right Cessation
- 2013-06-24 MX MX2014016054A patent/MX2014016054A/es unknown
- 2013-06-24 JP JP2015519023A patent/JP6181172B2/ja not_active Expired - Fee Related
- 2013-06-24 LT LTEP13731325.0T patent/LT2864291T/lt unknown
- 2013-06-24 UA UAA201500561A patent/UA115447C2/uk unknown
- 2013-06-24 WO PCT/EP2013/063118 patent/WO2014001247A1/fr not_active Ceased
- 2013-06-24 ME MEP-2016-292A patent/ME02590B/fr unknown
- 2013-06-24 NZ NZ703100A patent/NZ703100A/en not_active IP Right Cessation
- 2013-06-24 HU HUE13731325A patent/HUE032306T2/en unknown
- 2013-06-24 DK DK13731325.0T patent/DK2864291T3/en active
- 2013-06-24 US US14/408,876 patent/US9428460B2/en not_active Expired - Fee Related
- 2013-06-24 SI SI201330440A patent/SI2864291T1/sl unknown
- 2013-06-24 BR BR112014032538A patent/BR112014032538A2/pt not_active Application Discontinuation
- 2013-06-24 PL PL13731325T patent/PL2864291T3/pl unknown
- 2013-06-24 JO JOP/2013/0192A patent/JO3342B1/ar active
- 2013-06-24 MA MA37700A patent/MA37700B1/fr unknown
- 2013-06-24 RS RS20161149A patent/RS55500B1/sr unknown
- 2013-06-24 AU AU2013283543A patent/AU2013283543B2/en not_active Ceased
- 2013-06-24 PE PE2014002495A patent/PE20150154A1/es active IP Right Grant
- 2013-06-24 ES ES13731325.0T patent/ES2609455T3/es active Active
- 2013-06-24 CA CA2877786A patent/CA2877786C/fr not_active Expired - Fee Related
- 2013-06-24 KR KR20157001996A patent/KR20150023880A/ko not_active Ceased
- 2013-06-24 PT PT137313250T patent/PT2864291T/pt unknown
- 2013-06-24 HR HRP20161745TT patent/HRP20161745T1/hr unknown
- 2013-06-26 TW TW102122775A patent/TWI600646B/zh not_active IP Right Cessation
- 2013-06-26 UY UY0001034881A patent/UY34881A/es not_active Application Discontinuation
- 2013-06-26 AR ARP130102253 patent/AR091565A1/es unknown
-
2014
- 2014-12-09 IL IL236146A patent/IL236146B/en active IP Right Grant
- 2014-12-18 CR CR20140593A patent/CR20140593A/es unknown
- 2014-12-18 CL CL2014003443A patent/CL2014003443A1/es unknown
- 2014-12-18 CU CUP2014000144A patent/CU20140144A7/es unknown
- 2014-12-19 DO DO2014000295A patent/DOP2014000295A/es unknown
- 2014-12-19 EC ECIEPI201432516A patent/ECSP14032516A/es unknown
- 2014-12-19 CO CO14279115A patent/CO7170167A2/es unknown
- 2014-12-22 PH PH12014502869A patent/PH12014502869A1/en unknown
- 2014-12-25 TN TN2014000532A patent/TN2014000532A1/fr unknown
-
2016
- 2016-12-23 CY CY20161101343T patent/CY1118412T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35365B1 (fr) | Pyrimidines annelées substituées et leur utilisation | |
| MA42376B1 (fr) | Dérivés d'oxopyridine substitués | |
| MA34248B1 (fr) | 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation | |
| EP2844636A4 (fr) | Procédés pour le traitement de la rétinopathie diabétique et d'autres maladies ophtalmiques | |
| EA201500362A1 (ru) | Ингибиторы rho-киназы | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| MA33987B1 (fr) | Bloqueurs de canaux sodiques sensibles au potentiel | |
| UA118759C2 (uk) | Сполуки 3,4-дигідроізохінолін-2(1н)-ілу | |
| BR112013008140A8 (pt) | "compostos imidazotriazinona". | |
| EP2666471A4 (fr) | Composition pharmaceutique pour la traitement de la rate et de l'estomac, ainsi que procédé de préparation de cette composition | |
| MA38060A1 (fr) | Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| FR3012725B1 (fr) | Compositions d'agents de lutte biologique, leur procede de preparation et leurs utilisations | |
| MA38076A1 (fr) | Dérivés d'oxazolidin-2-one-pyrimidine | |
| EP2849787A4 (fr) | Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs | |
| MA38925A1 (fr) | Dérivés de phénylalanine substitués | |
| MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
| MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| MA39837B1 (fr) | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 | |
| MX2014014066A (es) | Compuestos de cromano. | |
| TN2014000532A1 (en) | N-[4-(Quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products | |
| PH12015500322A1 (en) | Tris(hetero)arylpyrazoles and use thereof | |
| EP2889039A4 (fr) | Préparation pour la prévention ou le traitement du diabète de type 1 | |
| EP2569018A4 (fr) | Ttc humanisé et procédés d'utilisation associés | |
| EP2862573A4 (fr) | Composition pour le traitement ou la prévention de maladies causées par une perméabilité vasculaire, contenant de l'imatinib ou un sel pharmaceutiquement acceptable de celui-ci en tant que principe actif |